分化型甲状腺癌术后患者<sup>131</sup>I治疗的辐射剂量与防护

成钊汀; 谭建; 成钊汀; 谭建

doi:10.3760/cma.j.issn.1673-4114.2014.02.010

[1]

中华人民共和国国家质量监督检验检疫总局. GB18871-2002电离辐射防护与辐射源安全基本标准[S].北京: 中国标准出版社, 2003.

[2]

International Commission on Radiological Protection. Release of patients after therapy with unsealed radionuclides[R]. ICRP Publication 94. Ann ICRP, 2004, 34(2): v-vi, 1-79.

[3]

European Commission. Radiation protection 97: radiation protection following iodine-131 therapy (exposures due to outpatients or discharged inpatients)[R]. Belgium: Office for Official Publications of the European Communities, 1998.

[4]

Vetter RJ. Regulations for radioiodine therapy in the United States: current status and the process of change[J]. Thyroid, 1997, 7(2): 209-211. doi: 10.1089/thy.1997.7.209

[5]

International Atomic Energy Agency. Nuclear medicine resources manual[R]. Vienna: International Atomic Energy Agency, 2006.

[6]

中华医学会内分泌学分会, 中华医学会外科学分会, 中国抗癌协会头颈肿瘤专业委员会, 等.甲状腺结节和分化型甲状腺癌诊治指南[J].中国肿瘤临床, 2012, 39(17): 1249-1272.

[7]

Kloos RT, Duvuuri V, Jhiang SM, et al. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma[J]. J Clin Endocrinol Metab, 2002, 87(12): 5817-5820. doi: 10.1210/jc.2002-020210

[8]

Jeong SY, Kim HW, Lee SW, et al. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms[J]. Thyroid, 2013, 23(5): 609-616. doi: 10.1089/thy.2012.0106

[9]

Kolbert KS, Pentlow KS, Pearson JR, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with ¹³¹I by use of ¹²⁴I PET and 3-dimensional internal dosimetry software[J]. J Nucl Med, 2007, 48(1): 143-149.

[10]

Jentzen W, Schneider E, Freudenberg L, et al. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer[J]. Nucl Med Commun, 2006, 27(8): 669-676. doi: 10.1097/00006231-200608000-00009

[11]

de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high ¹³¹I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer[J]. J Nucl Med, 2004, 45(9): 1549-1554.

[12]

Lassmann M, Hänscheid H, Reiners C, et al. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH[J]. J Nucl Med, 2005, 46(5): 900-901.

[13]

王建涛, 赵卫威, 刘斌, 等. ¹³¹I治疗对青少年分化型甲状腺癌患者外周血的影响[J].生物医学工程学杂志, 2011, 28(6): 1185-1188.

[14]

Pahlka RB, Sonnad JR. The effects of dialysis on ¹³¹I kinetics and dosimetry in thyroid cancer patients-a pharmacokinetic model[J]. Health Phys, 2006, 91(3): 227-237. doi: 10.1097/01.HP.0000214660.13440.64

[15]

Courbon F, Caselles O, Zerdoud S, et al. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications[J]. Q J Nucl Med Mol Imaging, 2006, 50(4): 363-370.

[16]

Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors[J]. Clin Endocrinol (Oxf), 2008, 69(3): 479-490. doi: 10.1111/j.1365-2265.2008.03222.x

[17]

Hyer S, Vini L, O′Connell M, et al. Testicular dose and fertility in men following I131 therapy for thyroid cancer[J]. Clin Endocrinol(Oxf), 2002, 56(6): 755-758. doi: 10.1046/j.1365-2265.2002.t01-1-01545.x

[18]

Garsi JP, Schlumberger M, Ricard M, et al. Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer[J]. Clin Endocrinol(Oxf), 2009, 71(6): 880-883. doi: 10.1111/j.1365-2265.2009.03561.x

[19]

Rosário PW, Barroso AL, Rezende LL, et al. Testicular function after radioiodine therapy in patients with thyroid cancer[J]. Thyroid, 2006, 16(7): 667-670. doi: 10.1089/thy.2006.16.667

[20]

Popova L, Hadjidekova V, Hadjieva T, et al. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma[J]. Hell J Nucl Med, 2005, 8(1): 54-57.

[21]

Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis[J]. Thyroid, 2009, 19(5): 451-457. doi: 10.1089/thy.2008.0392

[22]

Samerdokiene V, Atkocius V, Ofomala R. Radiation exposure received by the medical radiation workers in Lithuania at the Institute of Oncology, Vilnius University, 2004-2011[J]. Radiat Prot Dosimetry, 2013, 157(1): 152-157. doi: 10.1093/rpd/nct111

[23]

Piwowarska-Bilska H, Supinska A, Listewnik MH, et al. Radiation doses of employees of a Nuclear Medicine Department after implementation of more rigorous radiation protection methods[J]. Radiat Prot Dosimetry, 2013, 157(1): 142-145. doi: 10.1093/rpd/nct107

[24]

Piwowarska-Bilska H, Birkenfeld B, Gwardyś A, et al. Occupational exposure at the Department of Nuclear Medicine as a work environment: A 19-year follow-up[J]. Pol J Radiol, 2011, 76(2): 18-21.

[25]

Masood K, Ahmad M, Zafar J, et al. Assessment of occupational exposure among pakistani medical staff during 2007-2011[J]. Australas Phys Eng Sci Med, 2012, 35(3): 297-300. doi: 10.1007/s13246-012-0156-y

[26]

Kim CB, Jung JW, Jeong KH, et al. Measurements and prediction of the ambient dose rate from patient receiving radioiodine administration after thyroid ablation[J]. Radiat Prot Dosimetry, 2012, 151(1): 158-161. doi: 10.1093/rpd/ncr456

[27]

Barrington SF, Kettle AG, O′Doherty MJ, et al. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid[J]. Eur J Nucl Med, 1996, 23(2): 123-130. doi: 10.1007/BF01731834

[28]

Williams CE, Woodward AF. Management of the helpless patient after radioiodine ablation therapy-are we being too strict?[J]. Nucl Med Commun, 2005, 26(10): 925-928. doi: 10.1097/00006231-200510000-00012

[29]

Cherry SR, Sorenson JA, Phelps ME. Physics in nuclear medicine[M]. 4th ed. Philadelphia: Saunders, 2012.

[30]

Muir S, McLeod R, Dove R. Light-weight lead aprons-light on weight, protection or labelling accuracy?[J]. Australas Phys Eng Sci Med, 2005, 28(2): 128-130. doi: 10.1007/BF03178704

[31]

Fog LS, Collins P. Monte Carlo simulation of the dose to nuclear medicine staff wearing protective garments[J]. Australas Phys Eng Sci Med, 2008, 31(4): 307-316. doi: 10.1007/BF03178600

[32]

Young AM. Dose rates in nuclear medicine and the effectiveness of lead aprons: updating the department′s knowledge on old and new procedures[J]. Nucl Med Commun, 2013, 34(3): 254-264.

[33]

North DL. Uptake of ¹³¹I in households of thyroid cancer patients[J]. Health Phys, 2013, 104(4): 434-436. doi: 10.1097/HP.0b013e31828326ae

[34]

Rémy H, Coulot J, Borget I, et al. Thyroid cancer patients treated with ¹³¹I: radiation dose to relatives after discharge from the hospital[J]. Thyroid, 2012, 22(1): 59-63.

[35]

Gabriel S, Farman-Ara B, Bourrelly M, et al. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure[J]. Nucl Med Commun, 2011, 32(9): 829-833. doi: 10.1097/MNM.0b013e328347f1c2

[36]

de Carvalho JW, Sapienza M, Ono C, et al. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (¹³¹I)NaI, on an outpatient basis, be safe?[J]. Nucl Med Commun, 2009, 30(7): 533-541. doi: 10.1097/MNM.0b013e32832b79bc

[37]

Willegaignon J, Sapienza M, Ono C, et al. Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure[J]. Clin Nucl Med, 2011, 36(6): 440-445. doi: 10.1097/RLU.0b013e3182184fa0

[38]

Sisson JC, Freitas J, McDougall IR, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine ¹³¹I: practice recommendations of the American Thyroid Association[J]. Thyroid, 2011, 21(4): 335-346. doi: 10.1089/thy.2010.0403

[39]

Sapienza MT, Willegaignon J, Ono CR, et al. Radioiodine therapy of differentiated thyroid cancer: radiologic impact of out-patient treatment with 100 to 150 mCi Iodine-131 activities[J]. Arq Bras Endocrinol Metabol, 2009, 53(3): 318-325. doi: 10.1590/S0004-27302009000300004

[40]

de Carvalho AB Jr, Hunt J, Silva AX, et al. Use of a voxel phantom as a source and a second voxel phantom as a target to calculate effective doses in individuals exposed to patients treated with ¹³¹I[J]. J Nucl Med Technol, 2009, 37(1): 53-56. doi: 10.2967/jnmt.108.058172

[41]

Asli IN, Baharfard N, Shafiei B, et al. Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma[J]. Radiat Prot Dosimetry, 2010, 138(4): 376-381. doi: 10.1093/rpd/ncp269

[42]

Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?[J]. J Nucl Med, 2005, 46(2): 261-266.

[43]

Van Nostrand D, Atkins F, Bandaru VV, et al. Salivary gland protection with sialagogues: a case study[J]. Thyroid, 2009, 19(9): 1005-1008. doi: 10.1089/thy.2008.0381

[44]

Kulkarni K, Van Nostrand D, Atkins F, et al. Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered?[J]. Nucl Med Commun, 2014, 35(2): 210-216.

[45]

Fallahi B, Beiki D, Abedi SM, et al. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?[J]. Nucl Med Commun, 2013, 34(8): 777-786. doi: 10.1097/MNM.0b013e328362b1f2

[46]

Bhartiya US, Joseph LJ, Raut YS, et al. Effect of Ocimum sanctum, turmeric extract and vitamin E supplementation on the salivary gland and bone marrow of radioiodine exposed mice[J]. Indian J Exp Biol, 2010, 48(6): 566-571.

[47]

Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of ¹³¹I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial[J]. J Nucl Med, 2010, 51(4): 618-623. doi: 10.2967/jnumed.109.071449

[48]

Mendoza A, Shaffer B, Karakla D, et al. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction[J]. Thyroid, 2004, 14(2): 133-140. doi: 10.1089/105072504322880373

[49]

Ma C, Xie J, Jiang Z, et al. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(9): 1778-1785. doi: 10.1007/s00259-009-1368-6

[50]

Valdez IH, Wolff A, Atkinson JC, et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction[J]. Cancer, 1993, 71(5): 1848-1851. doi: 10.1002/1097-0142(19930301)71:5<1848::AID-CNCR2820710522>3.0.CO;2-F

[51]

Almeida JP, Kowalski LP. Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy: a pilot study[J]. Braz J Otorhinolaryngol, 2010, 76(5): 659-662. doi: 10.1590/S1808-86942010000500021

[52]

Koca G, Gültekin SS, Han U, et al. The efficacy of montelukast as a protective agent against ¹³¹I-induced salivary gland damage in rats: scintigraphic and histopathological findings[J]. Nucl Med Commun, 2013, 34(5): 507-517. doi: 10.1097/MNM.0b013e32835ffecd

[53]

Hosseinimehr SJ. Potential utility of radioprotective agents in the practice of nuclear medicine[J]. Cancer Biother Radiopharm, 2009, 24(6): 723-731. doi: 10.1089/cbr.2009.0635